Phase 2a

Safety, tolerability and efficacy of the glutaminyl cyclase inhibitor PQ912 in Alzheimer’s disease: results of a randomized, double-blind, placebo-controlled phase 2a study

Authors: Philip Scheltens, Merja Hallikainen, Timo Grimmer, Thomas Duning, Alida A Gouw, Charlotte E Teunissen, Alle Meije Wink, Paul Maruff, John Harrison, Caroline M van Baal, Suzanne Bruins, Inge Lues, Niels D Prins

Journal: Alzheimer's Research & Therapy

Year Published: 2018

Background: PQ912 is an inhibitor of the glutaminyl cyclase enzyme that plays a central role in the formation of synaptotoxic pyroglutamate-A-beta oligomers. We report on the first clinical study with PQ912 in subjects with biomarker-proven Alzheimer’s […]

Back to Publications